Sarpogrelate hydrochloride NEW
| Price | $41 | $66 | $122 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-01 |
Product Details
| Product Name: Sarpogrelate hydrochloride | CAS No.: 135159-51-2 |
| Purity: 99.42% | Supply Ability: 10g |
| Release date: 2024/11/01 |
Product Introduction
Bioactivity
| 名稱(chēng) | Sarpogrelate hydrochloride |
| 描述 | Sarpogrelate hydrochloride (MCI-9042) , a selective 5-HT2 antagonist, has been widely used as an anti-platelet agent for the treatment of PAD. Target: 5-HT2 Recepter Sarpogrelate is a drug which acts as an antagonist at the 5HT2A and 5-HT2B receptors. Sarpogrelate hydrochloride was shown to have the same affinity as ritanserin for 5-HT2A receptors, with a Ki value of 8.39 nM. Sarpogrelate hydrochloride lacked prominent 5-HT1-like, 5-HT3, beta, H1, H2 and M3 antagonist activity and weakly blocked alpha 1-adrenoceptors (pKB = 6.30). (S)-M-1 showed weak affinity for 5-HT1-like receptors (pKB = 6.30), alpha 1- (pKB = 6.80) and beta- (pKB = 6.54) adrenoceptors, while (R)-M-1 was a weak antagonist at histamine H1 receptors (pKB = 6.49). After 12 weeks of sarpogrelate administration, FBF and LBF responses during RH showed significant increases from 13.2 +/- 1.7 to 18.1 +/- 2.2 mL/min per 100 mL tissue (P < 0.01) and from 8.2 +/- 0.9 to 14.2 +/- 2.1 mL/min per 100 mL tissue (P < 0.05), respectively. Sarpogrelate hydrochloride -induced augmentation of FBF and LBF responses to RH was maintained at 24 weeks. Long-term oral administration of sarpogrelate improves vascular function in patients with PAD. |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 55 mg/mL (118.03 mM), Sonication is recommended. |
| 關(guān)鍵字 | Sarpogrelate hydrochloride | 5-HT Receptor | vascular | 5-HT2R | Inhibitor | inhibit | MCI9042 | thrombosis | Sarpogrelate Hydrochloride | 5-hydroxytryptamine Receptor | Sarpogrelate | Serotonin Receptor | MCI 9042 |
| 相關(guān)產(chǎn)品 | Alverine citrate | Olanzapine | Dapoxetine hydrochloride | CLOZAPINE N-OXIDE | Amitriptyline hydrochloride | Cloperastine hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride | Fluoxetine hydrochloride | Cinchonidine |
| 相關(guān)庫(kù) | 經(jīng)典已知活性庫(kù) | 神經(jīng)退行性疾病化合物庫(kù) | 疼痛相關(guān)化合物庫(kù) | 膜蛋白靶向化合物庫(kù) | 抗癌臨床化合物庫(kù) | 藥物功能重定位化合物庫(kù) | 抑制劑庫(kù) | 抗癌上市藥物庫(kù) | 已知活性化合物庫(kù) | GPCR靶點(diǎn)分子庫(kù) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/5mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $70.00/10mg |
VIP2Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2024-07-15 | |
| $1.10/1g |
VIP4Y
|
Dideu Industries Group Limited
|
2021-08-04 | |
| $3.00/3KG |
VIP7Y
|
Career Henan Chemical Co
|
2019-08-07 | |
| $3.00/3ASSAYS |
VIP7Y
|
Career Henan Chemical Co
|
2019-08-06 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY